The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 10,072 | 254,923 | SH | SOLE | 254,923 | 0 | 0 | ||
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 45,176 | 2,350,477 | SH | SOLE | 2,350,477 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 12,813 | 611,893 | SH | SOLE | 611,893 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 45,144 | 2,393,612 | SH | SOLE | 2,393,612 | 0 | 0 | ||
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 19,658 | 204,088 | SH | SOLE | 204,088 | 0 | 0 | ||
| Audentes Therapeutics, Inc. | COM | 05070R104 | 8,858 | 315,331 | SH | SOLE | 315,331 | 0 | 0 | ||
| Biohaven Pharmaceutical Holding Company Ltd. | COM | G11196105 | 2,226 | 53,345 | SH | SOLE | 53,345 | 0 | 0 | ||
| Blueprint Medicines Corporation | COM | 09627Y109 | 41,098 | 559,381 | SH | SOLE | 559,381 | 0 | 0 | ||
| CymaBay Therapeutics, Inc. | COM | 23257D103 | 7,721 | 1,508,091 | SH | SOLE | 1,508,091 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 10,297 | 998,278 | SH | SOLE | 998,278 | 0 | 0 | ||
| Immunomedics, Inc. | COM | 452907108 | 25,941 | 1,956,362 | SH | SOLE | 1,956,362 | 0 | 0 | ||
| Myokardia, Inc. | COM | 62857M105 | 15,575 | 298,666 | SH | SOLE | 298,666 | 0 | 0 | ||
| Natera, Inc. | COM | 632307104 | 9,396 | 286,468 | SH | SOLE | 286,468 | 0 | 0 | ||
| Replimune Group, Inc. | COM | 76029N106 | 7,918 | 569,662 | SH | SOLE | 569,662 | 0 | 0 | ||